20 articles
Niagen Bioscience launches a clinician-directed telehealth platform delivering at-home NAD+ subcutaneous injection kits to eligible US patients.
New research shows combining NMN supplementation with apigenin effectively reverses age-related muscle and bone decline in mice.
A new webinar tackles the real question in NAD+ supplementation: whether pills, injections, or pens produce meaningfully different health outcomes.
Nourish pairs AI tools with registered dietitians to tackle metabolic disease through behavior change, not just medication.
Research finds the absorption enhancer in oral semaglutide tablets affects gut bacteria and inflammation markers beyond its intended role.
A Phase 2 trial of Nivisnebart for early Alzheimer's is stopped after independent reviewers found it unlikely to slow disease progression.
Sinclair highlights apigenin's role in blocking CD38, the enzyme that degrades NAD+, calling the combined strategy a logical anti-aging approach.
A UC San Diego trial shows ION224 blocks liver fat production, cutting inflammation and scarring in 60% of MASH patients.
Clene's ALS therapy CNM-Au8 may qualify for FDA accelerated approval using a blood biomarker as a surrogate endpoint — a potential breakthrough for patients.
Singapore researchers find calcium alpha-ketoglutarate repairs brain cell communication and restores early memory abilities in Alzheimer's models.
New research shows popular supplements like NAC can alter sperm DNA, leading to facial and skull changes in offspring.
LNS8801 joins the NIA's gold-standard Interventions Testing Program, one of the most rigorous longevity drug trials in science.
A 20,000-person study validates IgG glycans as aging biomarkers, with therapeutic plasma exchange reducing glycan age by 0.4 years per month.
New research frames menopause as a mitochondrial energy crisis, positioning NMN as a targeted NAD⁺ precursor to restore cellular vitality.
Texas A&M researchers developed a nasal spray using extracellular vesicles that reversed brain aging, restored memory, and cut inflammation in just two doses.
A Harvard small molecule screen identified apigenin as a CD38 inhibitor, revealing how this common flavonoid raises cellular NAD levels.
LNS8801, a GPER agonist, enters NIA's rigorous Interventions Testing Program for lifespan and healthspan evaluation in 2026.
From NAD+ restoring aged muscle to meal timing accelerating aging, April's research roundup delivers actionable longevity insights.
Japanese scientists engineered hybrid vitamin K molecules that are 3x more potent at regrowing neurons, potentially transforming Alzheimer's treatment.
A major UF study finds glucosamine users with mild cognitive impairment are 25% more likely to develop dementia, raising urgent questions for older adults.
